Skip to content

Knowledge Hub

Learn how we're pioneering a new wave of precision medicine, explore our collection of publications, disease studies, webinars, thought leadership, and more

Newsletter signup


Our Philosophy

A deep dive into our unique approach and our mission to find better treatment options for patients with unmet medical needs


Genetic Risk Factors for ME/CFS Identified using Combinatorial Analysis

Groundbreaking study published in the Journal of Translational Medicine provides the first detailed genetic insights into the mechanisms underpinning ME/CFS

Disease Study

COVID-19 Disease Study

Understanding the disease biology of COVID-19 to find novel drug targets and new treatment options


Disease Mechanisms and Novel Target Discovery

Watch on-demand as PrecisionLife CEO, Dr Steve Gardner, joins Cyclica CEO, Naheed Kurji, to explore disease mechanisms and novel target discovery


The Best of PrecisionLife in 2022

2022 was a memorable year for techbio and PrecisionLife. Here we look back at twelve of our highlights.


Cell Patterns: INDx Systematic Indication Extension

Paper demonstrating the potential of indication extension to systematically reposition hundreds of drugs into new indications


Combinatorial analytics: An Essential Tool for the Delivery of Precision Medicine

An Opinion, published in the new Open Access Journal Artificial Intelligence in the Life Sciences from Elsevier, describes the need to extend our current analytical methods to effectively interrogate population data sets

Disease Study

Alzheimer's Disease Study

Reducing the risk of future Alzheimer's disease clinical trial failures by identifying patient subgroups


Proving the Power of Combinatorial Analytics

A summary of how >70% of associated novel gene targets for severe COVID-19 identified with combinatorial analytics in May 2020 have now been independently validated

Sign Up

Subscribe to our blog